19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
15:47 , Aug 30, 2018 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
17:11 , Apr 14, 2017 |  BC Week In Review  |  Company News

BMS, Roche deal

Bristol-Myers granted Roche rights to BMS-986089, a fusion protein designed to suppress myostatin (MSTN; GDF8). According to ClinicalTrials.gov, BMS-986089 is in Phase I/II testing to treat Duchenne muscular dystrophy (DMD) in ambulatory patients ages 5-10....
19:32 , Apr 13, 2017 |  BC Extra  |  Company News

BMS out-licenses programs to Biogen, Roche

Bristol-Myers Squibb Co. (NYSE:BMY) said Thursday it out-licensed a pair of programs to Biogen Inc. (NASDAQ:BIIB) and Roche (SIX:ROG; OTCQX:RHHBY). Spokesperson Chrissy Trank told BioCentury the deals end BMS's clinical development of therapies for genetically...